Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Affiliations

• ¹ Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
• ² Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, New York, NJ USA.
• ³ Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
• ⁴ Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
• ⁵ Department of Biomedicine, Aarhus University, Aarhus, Denmark.
• ⁶ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
• ⁷ Kuros Biosciences BV, Bilthoven, the Netherlands.
• ⁸ The School of Engineering and Materials Science, Queen Mary University of London, London, UK.
• ⁹ Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands t.mutis@vumc.nl r.groen@vumc.nl.